دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Flashback Foreword: Estrogen Receptor by Immunohistochemistry in Breast Cancer.
Ganz, Patricia A. MD 1,2,
doi : 10.1200/JCO.22.02671
Volume 41(7) pgs. 1329-1497 March 1, 2023
Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast Cancer.
Harvey, Jennet M.; Clark, Gary M.; Osborne, C. Kent; Allred, D. Craig
doi : 10.1200/JCO.22.02500
Immunohistochemistry (IHC) is a newer technique for assessing the estrogen receptor (ER) status of breast cancers, with the potential to overcome many of the shortcomings associated with the traditional ligand-binding assay (LBA).
Back to the Beginning: The Role of Ovarian Suppression in Management of Hormone Sensitive Breast Cancer in Premenopausal Women.
Connolly, Roisin M. MBBCh, MD 1,,; Miller, Kathy D. MD 2,
doi : 10.1200/JCO.22.02319
How We Manage Newly Diagnosed Multiple Myeloma With Circulating Tumor Cells.
van de Donk, Niels W.C.J. MD, PhD 1,2,
doi : 10.1200/JCO.22.02114
Understanding Modern Medical Centers: Beyond Simone-Intersectional Maxims for a New Era.
Graff, Stephanie L. MD 1,; Wildes, Tanya MD 2,; Duma, Narjust MD 3,; Dizon, Don S. MD 1,; LoConte, Noelle K. MD 4,; Mitchell, Edith MD 5,; Murphy, Martina C. MD 6,; Perez, Edith A. MD 7,; Temkin, Sarah M. MD 8,; Kunz, Pamela L. MD 9,; Winkfield, Karen M. MD 10,
doi : 10.1200/JCO.22.01060
Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211).
Kunz, Pamela L. MD 1,; Graham, Noah T. MS 2; Catalano, Paul J. ScD 2,; Nimeiri, Halla S. MD 3,; Fisher, George A. MD, PhD 4,; Longacre, Teri A. MD 4,; Suarez, Carlos J. MD 4; Martin, Brock A. MD 5; Yao, James C. MD 6,; Kulke, Matthew H. MD 7,; Hendifar, Andrew E. MD 8,; Shanks, James C. MD 9; Shah, Manisha H. MD 10,; Zalupski, Mark M. MD 11,; Schmulbach, Edmond L. MD 12,; Reidy-Lagunes, Diane L. MD 13,; Strosberg, Jonathan R. MD 14,; O'Dwyer, Peter J. MD 15,; O'Dwyer, Peter J. MD 15,; Benson, Al B. III MD 3,
doi : 10.1200/JCO.22.01013
Patients with advanced pancreatic neuroendocrine tumors (NETs) have few treatment options that yield objective responses. Retrospective and small prospective studies suggest that capecitabine and temozolomide are associated with high response rates (RRs) and long progression-free survival (PFS).
Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT.
Francis, Prudence A. MD 1,2,3,; Fleming, Gini F. MD 4,; Lang, Istvan MD 5,6; Ciruelos, Eva M. MD, PhD 7,; Bonnefoi, Herve R. MD 8,; Bellet, Meritxell MD 9,; Bernardo, Antonio MD 10; Climent, Miguel A. MD 11,; Martino, Silvana DO 12,; Bermejo, Begona MD, PhD 13,14,; Burstein, Harold J. MD, PhD 15,; Davidson, Nancy E. MD 16; Geyer, Charles E. Jr MD 17,; Walley, Barbara A. MD 18,; Ingle, James N. MD 19; Coleman, Robert E. MD, MBBS, FRCP 20,21,22,; Muller, Bettina MD 23; Le Du, Fanny MD 24,; Loibl, Sibylle MD, PhD 25,26,; Winer, Eric P. MD 15,27,28,; Ruepp, Barbara PharmD 29; Loi, Sherene MD, PhD 30,; Colleoni, Marco MD 31,; Coates, Alan S. MD 32,; Gelber, Richard D. PhD 33,; Goldhirsch, Aron MD 34; Regan, Meredith M. ScD 35,; for the SOFT Investigators and the International Breast Cancer Study Group (a division of ETOP IBCSG Partners Foundation)
doi : 10.1200/JCO.22.01065
AB Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available.
Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials.
Pagani, Olivia MD 1,2,,; Walley, Barbara A. MD 3,; Fleming, Gini F. MD 4,; Colleoni, Marco MD 5,; Lang, Istvan MD, PhD 6,7; Gomez, Henry L. MD, PhD 8,9,; Tondini, Carlo MD 10,; Burstein, Harold J. MD, PhD 11,; Goetz, Matthew P. MD 12,; Ciruelos, Eva M. MD, PhD 13,; Stearns, Vered MD 14,; Bonnefoi, Herve R. MD 15,; Martino, Silvana DO 16,; Geyer, Charles E. Jr MD 17,; Chini, Claudio MD 18; Puglisi, Fabio MD, PhD 19,; Spazzapan, Simon MD 20,; Ruhstaller, Thomas MD 21,; Winer, Eric P. MD 22,11,; Ruepp, Barbara PharmD 23; Loi, Sherene MD, PhD 24,; Coates, Alan S. MD 25,; Gelber, Richard D. PhD 26,; Goldhirsch, Aron MD 27,+; Regan, Meredith M. ScD 28,; Francis, Prudence A. MD 29,30; for the SOFT and TEXT Investigators and the International Breast Cancer Study Group (a division of ETOP IBCSG Partners Foundation)
doi : 10.1200/JCO.22.01064
AB Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available.
More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia-Like Multiple Myeloma.
Jelinek, Tomas MD, PhD 1; Bezdekova, Renata PhD 2; Zihala, David PhD 1; Sevcikova, Tereza PhD 1,3; Anilkumar Sithara, Anjana MSc 1,3; Pospisilova, Lenka MSc 4; Sevcikova, Sabina PhD 5; Polackova, Petra MSc 2; Stork, Martin MD, PhD 6; Knechtova, Zdenka MCs 6; Venglar, Ondrej MSc 3; Kapustova, Veronika MSc 1; Popkova, Tereza MD 1; Muronova, Ludmila MD 1; Chyra, Zuzana PhD 1; Hrdinka, Matous PhD 1; Simicek, Michal PhD 1; Garces, Juan-Jose PhD 7; Puig, Noemi MD, PhD 8; Cedena, Maria-Teresa MD, PhD 9; Jurczyszyn, Artur MD, PhD 10; Castillo, Jorge J. MD, PhD 11; Penka, Miroslav MD 2; Radocha, Jakub MD, PhD 12; Mateos, Maria Victoria MD 8; San-Miguel, Jesus F. MD, PhD 7; Paiva, Bruno PhD 7; Pour, Ludek MD, PhD 5; Rihova, Lucie PhD 2; Hajek, Roman MD, PhD 1,
doi : 10.1200/JCO.22.01226
Primary plasma cell leukemia (PCL) is the most aggressive monoclonal gammopathy. It was formerly characterized by >= 20% circulating plasma cells (CTCs) until 2021, when this threshold was decreased to >= 5%. We hypothesized that primary PCL is not a separate clinical entity, but rather that it represents ultra-high-risk multiple myeloma (MM) characterized by elevated CTC levels.
Graded Cardiac Response Criteria for Patients With Systemic Light Chain Amyloidosis.
Muchtar, Eli MD 1,; Dispenzieri, Angela MD 1,; Wisniowski, Brendan MBBS 2; Palladini, Giovanni MD, PhD 3,4,; Milani, Paolo MD, PhD 3,4,; Merlini, Giampaolo MD 3,4; Schonland, Stefan MD 5,; Veelken, Kaya MD 5; Hegenbart, Ute MD 5,; Geyer, Susan M. PhD 6,; Kumar, Shaji K. MD 1,; Kastritis, Efstathios MD 7,; Dimopoulos, Meletios A. MD 7,; Liedtke, Michaela MD 8,; Witteles, Ronald MD 8,; Sanchorawala, Vaishali MD 9,; Szalat, Raphael MD 9; Landau, Heather MD 10,; Petrlik, Erica MD 10,; Lentzsch, Suzanne MD, PhD 11,; Coltoff, Alexander MD 11; Blade, Joan MD, PhD 12,; Cibeira, Maria Teresa MD, PhD 12,; Cohen, Oliver MD 2; Foard, Darren MD 2; Wechalekar, Ashutosh MD 2,; Gertz, Morie A. MD 1,
doi : 10.1200/JCO.22.00643
Binary cardiac response assessment using cardiac biomarkers is prognostic in light chain amyloidosis. Previous studies suggested four-level cardiac responses using N-terminal prohormone of brain natiuretic peptide improves prognostic prediction.
Outcomes of Childhood Noninfant Acute Lymphoblastic Leukemia With 11q23/KMT2A Rearrangements in a Modern Therapy Era: A Retrospective International Study.
Attarbaschi, Andishe MD 1,,; Moricke, Anja MD 2,; Harrison, Christine J. PhD 3; Mann, Georg MD 1; Baruchel, Andre MD 4,; De Moerloose, Barbara MD 5,; Conter, Valentino MD 6,; Devidas, Meenakshi PhD 7,; Elitzur, Sarah MD 8,9,; Escherich, Gabriele MD 10; Hunger, Stephen P. MD 11,; Horibe, Keizo MD 12,; Manabe, Atsushi MD 13; Loh, Mignon L. MD 14,15,; Pieters, Rob PhD 16,; Schmiegelow, Kjeld MD 17,18,; Silverman, Lewis B. MD 19,; Stary, Jan MD 20; Vora, Ajay MD 21,; Pui, Ching-Hon MD 22,23,; Schrappe, Martin PhD 2,; Zimmermann, Martin PhD 24; on behalf of the Ponte-di-Legno Childhood Acute Lymphoblastic Leukemia Working Group
doi : 10.1200/JCO.22.01297
We aimed to study prognostic factors and efficacy of allogeneic hematopoietic stem-cell transplantation (allo-HSCT) in first remission of patients with noninfant childhood acute lymphoblastic leukemia (ALL) with 11q23/KMT2A rearrangements treated with chemotherapy regimens between 1995 and 2010.
Clonal Hematopoiesis and Risk of Incident Lung Cancer.
Tian, Ruiyi MPH 1,2; Wiley, Brian MS 3; Liu, Jie MBBS, MPH 3; Zong, Xiaoyu MPH 1; Truong, Buu MD 4,5,6; Zhao, Stephanie BS 7; Uddin, Md Mesbah PhD 4,6; Niroula, Abhishek PhD 6,8,9; Miller, Christopher A. PhD 3,10; Mukherjee, Semanti PhD 11,12,; Heiden, Brendan T. MD, MPHS 13; Luo, Jingqin PhD 1,10; Puri, Varun MD, MSCI 13,; Kozower, Benjamin D. MD, MPH 13; Walter, Matthew J. MD 3,10; Ding, Li PhD 3,10,14; Link, Daniel C. MD 3,10; Amos, Christopher I. PhD 15,16,17; Ebert, Benjamin L. MD, PhD 9,18,19,; Govindan, Ramaswamy MD 3,10,; Natarajan, Pradeep MD, MMSC 4,6,20,; Bolton, Kelly L. MD, PhD 3; Cao, Yin ScD, MPH 1,10,,
doi : 10.1200/JCO.22.00857
To prospectively examine the association between clonal hematopoiesis (CH) and subsequent risk of lung cancer. METHODS: Among 200,629 UK Biobank (UKBB) participants with whole-exome sequencing, CH was identified in a nested case-control study of 832 incident lung cancer cases and 3,951 controls (2006-2019) matched on age and year at blood draw, sex, race, and smoking status.
Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial.
Qin, Shukui MD 1,; Chen, Zhendong MD 2; Fang, Weijia MD 3; Ren, Zhenggang MD 4,; Xu, Ruocai MD 5; Ryoo, Baek-Yeol MD 6; Meng, Zhiqiang MD 7; Bai, Yuxian MD 8; Chen, Xiaoming MD 9,10; Liu, Xiufeng MD 1; Xiao, Juxiang MD 11; Ho, Gwo Fuang MRCP, MBChB 12,; Mao, Yimin MD 13; Wang, Xin MD 14; Ying, Jieer MD 15; Li, Jianfeng MD 16; Zhong, Wenyan PhD 17,; Zhou, Yu MD 17; Siegel, Abby B. MD 18,; Hao, Chunyi MD 19
doi : 10.1200/JCO.22.00620
We evaluated the efficacy and safety of pembrolizumab in patients from Asia with previously treated advanced hepatocellular carcinoma (HCC). METHODS: In a double-blind, phase III trial, 453 patients with advanced HCC and progression during or after treatment with or intolerance to sorafenib or oxaliplatin-based chemotherapy were randomly assigned in a 2:1 ratio to receive pembrolizumab (200 mg) or placebo once every 3 weeks for <= 35 cycles plus best supportive care.
Phase IIb Randomized, Placebo-Controlled, Dose-Escalating, Double-Blind Study of Cannabidiol Oil for the Relief of Symptoms in Advanced Cancer (MedCan1-CBD).
Hardy, Janet MD, FRACP 1,2,,; Greer, Ristan PhD 2,3; Huggett, Georgie BN 1; Kearney, Alison FRACP 4,5; Gurgenci, Taylan FRACGP 1,2; Good, Phillip PhD, FRACP 1,2,6,
doi : 10.1200/JCO.22.01632
To determine whether cannabidiol (CBD) oil can improve symptom distress in patients with advanced cancer receiving palliative care. METHODS: Participants were adults with advanced cancer and symptom distress (Edmonton Symptom Assessment Scale [ESAS] total score of >= 10/90) who received titrated CBD oil 100 mg/mL, 0.5 mL once daily to 2 mL three times a day, or matched placebo for 28 days.
Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma.
Ahluwalia, Manmeet S. MD 1,; Reardon, David A. MD 2,; Abad, Ajay P. MD 3; Curry, William T. MD 4,; Wong, Eric T. MD 5,; Figel, Sheila A. PhD 6,7,; Mechtler, Laszlo L. MD 3,; Peereboom, David M. MD 1,; Hutson, Alan D. PhD 8; Withers, Henry G. PhD 8,; Liu, Song PhD 8,; Belal, Ahmed N. MD 9; Qiu, Jingxin MD, PhD 10; Mogensen, Kathleen M. NP 3; Dharma, Sanam S. PhD 6,; Dhawan, Andrew MD 11; Birkemeier, Meaghan T. BS 6; Casucci, Danielle M. BS 6,7; Ciesielski, Michael J. PhD 6,7,; Fenstermaker, Robert A. MD 6,7,,
doi : 10.1200/JCO.22.00996
Despite intensive treatment with surgery, radiation therapy, temozolomide (TMZ) chemotherapy, and tumor-treating fields, mortality of newly diagnosed glioblastoma (nGBM) remains very high.
Vaccines Targeting Gliomas: Antigens Matter.
Platten, Michael MD 1,2,3,4,; Grassl, Niklas MD 1,2,4
doi : 10.1200/JCO.22.02616
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline.
Shah, Manish A. MD 1,; Kennedy, Erin B. MHSc 2; Alarcon-Rozas, Ashley E. MD, MBA 3; Alcindor, Thierry MD 4,; Bartley, Angela N. MD 5; Malowany, Aubrey Belk BS 6; Bhadkamkar, Nishin A. MD 7; Deighton, Dana C. BA 8,; Janjigian, Yelena MD 9,; Karippot, Asha MD 10; Khan, Uqba MD 1,; King, Daniel A. MD, PhD 11,; Klute, Kelsey MD 12,; Lacy, Jill MD 13,; Lee, James J. MD, PhD 14,; Mehta, Rutika MD, MPH 15,; Mukherjee, Sarbajit MD, MS 16,; Nagarajan, Arun MD 17; Park, Haeseong MD, MPH 18,; Saeed, Anwaar MD 19,; Semrad, Thomas J. MD, MAS 20; Shitara, Kohei MD 21,; Smyth, Elizabeth MD 22,; Uboha, Nataliya V. MD, PhD 23,; Vincelli, Melani 24; Wainberg, Zev MD 25,; Rajdev, Lakshmi MD 26,
doi : 10.1200/JCO.22.02331
To develop recommendations involving targeted therapies for patients with advanced gastroesophageal cancer. METHODS: The American Society of Clinical Oncology convened an Expert Panel to conduct a systematic review of relevant studies and develop recommendations for clinical practice.
Redefining Gleason 6 Prostate Cancer Nomenclature: The Surgeon's Perspective.
Baboudjian, Michael MD; Roupret, Morgan MD, PhD; Ploussard, Guillaume MD, PhD
doi : 10.1200/JCO.22.01621
Reply to M. Baboudjian et al.
Eggener, Scott E. MD; Berlin, Alejandro MD; Vickers, Andrew J. PhD; Paner, Gladell P. MD; Wolinsky, Howard; Cooperberg, Matthew R. MD
doi : 10.1200/JCO.22.02061
Acquired Genomic Alterations From First-Line Anti-EGFR Chemotherapy in Advanced Colorectal Cancer: Improving Study Design and Data Analysis.
Yu, Yang MD; Shi, Qianling MD; Chen, Hao MD
doi : 10.1200/JCO.22.02296
Reply to Y. Yu et al.
Raghav, Kanwal MD; Kopetz, Scott MD; Yuan, Ying PhD
doi : 10.1200/JCO.22.02588
Conditioning Regimen in Patients With Adult Acute B Lymphoblastic Leukemia.
Shibusawa, Motoharu MD; Tanimoto, Tetsuya MD
doi : 10.1200/JCO.22.02230
